COMMUNIQUÉS West-GlobeNewswire

Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019
25/04/2019
Press Release 25 April 2019 Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2019 At the Annual General Meeting (the "AGM") of Immunicum AB (publ), reg. no 556629-1786, (the "Company"), on [...]
Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019
25/04/2019
Conference Call and Webcast Scheduled for Thursday, May 9 at 8:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, [...]
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019
25/04/2019
BUFFALO, N.Y., April 25, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
NeuroMetrix Reports Q1 2019 Financial Results
25/04/2019
WALTHAM, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2019. The Company develops and markets novel [...]
Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
25/04/2019
CRANBURY, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 8:30 a.m. ET to [...]
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
25/04/2019
WAYNE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that it has [...]
Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019
25/04/2019
THE WOODLANDS, Texas, April 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2019 financial results on Wednesday, May 1, 2019 before market opens. Management will [...]
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results
25/04/2019
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]
Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
25/04/2019
-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma -Phase 2 clinical data on lead [...]
MyDx Announces 2018 Fiscal Year Results and Shareholder Update
25/04/2019
SAN DIEGO, CA, April 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – MyDx, Inc. ( OTC: MYDX ), a leader in science based cannabis health technologies, announced that it has filed its 2018 10-K annual report and is [...]
Decision by the Board of Directors to acquire own shares
25/04/2019
ORION CORPORATION STOCK EXCHANGE RELEASE 25 APRIL 2019 at 12.30 EEST Decision by the Board of Directors to acquire own shares The Board of Directors of Orion Corporation decided on 25 April 2019 on a share acquisition [...]
Orion Group Interim Report January-March 2019
25/04/2019
ORION CORPORATION INTERIM REPORT JANUARY-MARCH 2019 25 APRIL 2019 at 12.00 EEST Orion Group Interim Report January-March 2019 Net sales in January-March 2019 totalled EUR 241 million (EUR 247 million in January-March [...]
Philips launches IntelliSpace Radiation Oncology to accelerate time from patient referral to the start of treatment
25/04/2019
April 25, 2019 Intelligent patient management solutions on display at ESTRO 2019 to complement latest radiotherapy imaging and treatment planning innovations Amsterdam, the Netherlands and Milan, Italy – Royal Philips ( [...]
LIDDS invited to speak at Formulation and Drug Delivery Congress in London
25/04/2019
Director of Pharmaceutical R&D, Stefan Grudén, has been invited to present at the Annual Formulation and Drug Delivery Congress being held in London on 29-30 April. This annual congress is an important event for [...]
Financière de Tubize SA : Approbation du dividende
25/04/2019
Communiqué de presse FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: aspijcke, directeur, aspijcke@icloud.com Approbation du dividende Information réglementée 24 avril 2019 L'assemblée générale [...]
Biocartis Group NV: BIOCARTIS Q1 2019 BUSINESS UPDATE
25/04/2019
PRESS RELEASE : REGULATED INFORMATION Thursday 25 April 2019, 07:00 CEST BIOCARTIS Q1 2019 BUSINESS UPDATE Mechelen, Belgium , 25 April 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular [...]
ACACIA PHARMA ANNOUNCES POSITIVE PHASE 3 BARHEMSYS® RESCUE TREATMENT DATA TO BE PRESENTED AT THE ANNUAL CONGRESS OF ENHANCED RECOVERY AND PERIOPERATIVE MEDICINE
25/04/2019
Cambridge, UK and Indianapolis, US – 25 April 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that additional data and analyses from its positive Phase 3 clinical trial of [...]
Bone Therapeutics announces publication of Annual Report 2018 and Extraordinary General Meeting on 23 May 2019
25/04/2019
Regulated information Gosselies, Belgium, 25 April 2019, 7 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]
Bone Therapeutics annonce la publication de son Rapport Annuel 2018 et la tenue d’une Assemblée Générale Extraordinaire le 23 mai 2019
25/04/2019
Information réglementée Gosselies, Belgique, le 25 avril 2019, 7h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE, éligible PEA-PME), société de thérapie cellulaire osseuse qui répond à d’importants [...]

Pages